Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T35842 | ||||
Target Name | Melanocortin receptor 1 (MC1R) | ||||
Type of Target |
Successful |
||||
Drug Potency against Target | Drug Info | IC50 = 0.2 nM | [6] | ||
Drug Info | IC50 = 600 nM | [6] | |||
Drug Info | Ki = 9.91 nM | [1] | |||
Drug Info | IC50 = 1000 nM | [3] | |||
Drug Info | IC50 = 2000 nM | [5] | |||
Drug Info | Ki = 49.42 nM | [1] | |||
Drug Info | IC50 = 707 nM | [5] | |||
Drug Info | IC50 = 615 nM | [7] | |||
Drug Info | Ki = 2.73 nM | [1] | |||
Ac-dR[CEHdFRWC]-NH2 | Drug Info | Ki = 16.78 nM | [1] | ||
Ac-His-D-Phe-Arg-2-Nal-NHCH3 | Drug Info | Ki = 13 nM | [4] | ||
Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2 | Drug Info | IC50 = 1 nM | [6] | ||
Ac-R[CEHdFRWC]-NH2 | Drug Info | Ki = 10.34 nM | [1] | ||
Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3 | Drug Info | Ki = 4520 nM | [4] | ||
Ac-YK[CEHdFRWC]-NH2 | Drug Info | Ki = 15.76 nM | [1] | ||
Ac-YRMEHdFRWG-NH2 | Drug Info | Ki = 0.21 nM | [1] | ||
Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2 | Drug Info | Ki = 121.3 nM | [1] | ||
Ac-YR[CEH(pCl-dF)RWC]-NH2 | Drug Info | Ki = 8.22 nM | [1] | ||
Ac-YR[CEHdFRWC]-NH2 | Drug Info | Ki = 17.12 nM | [1] | ||
Ac-YR[CEHdFRWC]SPPKD-NH2 | Drug Info | Ki = 0.57 nM | [1] | ||
Ac-YR[CEHFRWC]-NH2 | Drug Info | Ki = 147.07 nM | [1] | ||
Ac-[CEHdFRWC]-NH2 | Drug Info | Ki = 67.09 nM | [1] | ||
AEKKDEGPYRMEHFRWGSPPKD | Drug Info | Ki = 0.89 nM | [1] | ||
C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2 | Drug Info | IC50 = 412 nM | [5] | ||
C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 | Drug Info | IC50 = 410 nM | [5] | ||
C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 | Drug Info | IC50 = 1500 nM | [3] | ||
C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 | Drug Info | IC50 = 1400 nM | [3] | ||
C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 | Drug Info | IC50 = 1000 nM | [3] | ||
C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2 | Drug Info | IC50 = 3000 nM | [3] | ||
C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 | Drug Info | IC50 = 4000 nM | [3] | ||
GPYRMEHFRWGSPPKD-NH2 | Drug Info | Ki = 0.51 nM | [1] | ||
NDP-SYSMEHFRWGKPVG | Drug Info | Ki = 0.1 nM | [1] | ||
Tic-D-Phe-Arg-2-Nal-NHCH3 | Drug Info | Ki = 2276 nM | [2] | ||
References | |||||
REF 1 | Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. | ||||
REF 2 | Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1721-5. | ||||
REF 3 | Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. | ||||
REF 4 | Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73. | ||||
REF 5 | Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. | ||||
REF 6 | Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35. | ||||
REF 7 | Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. J Med Chem. 1997 Jul 4;40(14):2133-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.